Added RGEN at 3.30.
Good move up lately.
3 Insider buys, no sells.
WALTHAM, Mass., Feb. 11 /PRNewswire-FirstCall/-- Repligen Corporation (Nasdaq: RGEN - News) today reported results for the third quarter of fiscal year 2004 ended December 31, 2003. Total revenue for the quarter was $1,321,000 compared to total revenue of $2,417,000 for the third quarter of fiscal year 2003. Gross profit for the quarter was $539,000, or 41% of revenue compared to $1,276,000, or 53% of revenue for the third quarter of fiscal year 2003. Operating expenses for the third quarter of fiscal year 2004 were $2,766,000 compared to $2,182,000, for the third quarter in fiscal year 2003. The net loss for the third quarter of fiscal year 2004 was $2,127,000 or $.07 per share, compared to a net loss of $766,000 or $.03 per share for the third quarter of fiscal year 2003. Cash and investments as of December 31, 2003 were $25,659,000.
Summary: Nonprofitable, but insiders buys make this biotech an interesting stock. |
